Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future

• Published in: Clinical research in cardiology Vol. 109; no. 9; pp. 1079 - 1098
• Main Authors: Wintrich, Jan, Kindermann, Ingrid, Ukena, Christian, Selejan, Simina, Werner, Christian, Maack, Christoph, Laufs, Ulrich, Tschöpe, Carsten, Anker, Stefan D., Lam, Carolyn S. P., Voors, Adriaan A., Böhm, Michael
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2020; Springer Nature B.V
• Subjects: Aminobutyrates - administration & dosage; Aminobutyrates - pharmacology; Angiotensin Receptor Antagonists - administration & dosage; Angiotensin Receptor Antagonists - pharmacology; Animals; Biomarkers; Biphenyl Compounds - administration & dosage; Biphenyl Compounds - pharmacology; Cardiology; Clinical trials; Congestive heart failure; Drug Combinations; Ejection fraction; Fibrosis; Heart failure; Heart Failure - diagnosis; Heart Failure - physiopathology; Heart Failure - therapy; Hospitalization - statistics & numerical data; Humans; Medicine; Medicine & Public Health; Na+/glucose cotransporter; Patients; Phenotypes; Randomized Controlled Trials as Topic; Review; Stroke Volume - physiology; Subgroups; Valsartan - administration & dosage; Valsartan - pharmacology; Heart failure; Pharmacotherapy in HFpEF; Device therapy; Preserved ejection fraction; LCZ696

In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction (HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with preserved ejection fraction (HFpEF). Moreover, to this day, diagnosis of HFpEF remains controversial. However,...